Abstracts tagged "Behcet’s syndrome"

Abstract Number: 1790 • 2018 ACR/ARHP Annual Meeting
An Unmet Need for Oral Ulcer Activity in Patients with Behcet’s Disease: A Multi-National Study
Gonca Mumcu¹, Adebowale Adesanya², Aysun Aksoy³, Joice Moraes Faria M Belem⁴, Natalia Borges Cardin⁴, Fatma Alibaz-Oner⁵, Tulin Ergun⁶, Nevsun Inanc⁷, Alexandre W.S. Souza⁸, Wafa Madanat⁹, Farida Fortune¹⁰ and Haner Direskeneli⁷, ¹Department of Health Management, Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ²Barts and The London, School of Medicine and Dentistry, Institute of Dentistry, Clinical and Diagnostic Oral Sciences, London, UK, London, United Kingdom, ³Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ⁴Rheumatology, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ⁵Şerifali mahallesi İbrahim Hakkı sokak. Lavella 4 sitesi. B blok, D:22 Umraniye, Şerifali mahallesi İbrahim Hakkı sokak. Lavella 4 sitesi. B blok, D:22 Umraniye, Istanbul, Turkey, ⁶Department of Dermatology, Faculty of Medicine, Marmara University, Istanbul, Turkey, ⁷Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁸Rheumatology Division, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁹Jordan’s Friends of Behcet’s disease Patients Society, Medical department, Amman, Jordan, Amman, Jordan, ¹⁰Dental Institute, Barts and The London NHS Trust, London, United Kingdom
Background/Purpose: Efficacy of current management approaches for oral ulcer treatment in routine clinical practice is insufficiently explored in Behcet’s disease (BD) patients. The aim of…
Abstract Number: 1811 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Interferon α2a As an Add-on Treatment for Refractory Behcet’s Uveitis
Jing Shi¹, Chan Zhao², Jiaxin Zhou³, JinJing Liu¹, Fei Gao², Xiaofeng Zeng⁴, Meifen Zhang² and Wenjie Zheng¹, ¹Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Department of Ophthalmology, Peking Union Medical College Hospital, Beijing, China, ³Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, ⁴Rheumatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China
Background/Purpose: Uveitis is one of the leading causes of morbidity in Behcet’s patients which may result in irreversible vision loss. Evidence is accumulating that interferon…
Abstract Number: 1791 • 2018 ACR/ARHP Annual Meeting
Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome in a Phase III Study: A Prespecified Analysis By Baseline Patient Demographics and Disease Characteristics
Gulen Hatemi¹, Alfred Mahr², Mitsuhiro Takeno³, Do-Young Kim⁴, Melike Melikoglu¹, Sue Cheng⁵, Shannon McCue⁵, Maria Paris⁵, Mindy Chen⁵ and Yusuf Yazici⁶, ¹Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ²Hospital Saint-Louis, University Paris Diderot, Paris, France, ³Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁴Yonsei University College of Medicine and Severance Hospital, Seoul, Korea, Republic of (South), ⁵Celgene Corporation, Summit, NJ, ⁶New York University School of Medicine, New York, NY
Background/Purpose: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by recurrent oral ulcers (OU) that can be disabling and negatively affect quality of life.…
Abstract Number: 1812 • 2018 ACR/ARHP Annual Meeting
Characterization and Prevalence of Morbus Behçet in Switzerland
Sabine Adler¹, Rahel Villiger², Lukas Buetikofer³ and Peter M. Villiger⁴, ¹Department of Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ²Rheumatology, Immunology and Allergology, University Hospital Bern, Switzerland, Bern, Switzerland, ³Clinical Trials Unit, University of Bern, Bern, Switzerland, ⁴Rheumatology and Clin Immunol, Bern, Switzerland
Background/Purpose: To evaluate the clinical presentation of patients with Morbus Behçet (MB) in a cohort from Switzerland and to calculate the prevalence of MB in…
Abstract Number: 1794 • 2018 ACR/ARHP Annual Meeting
Venous Vessel Wall Thickness in Lower Extremity Is Increased in Male Behcet’s Disease Patients
Fatma Alibaz-Oner¹, Rabia Ergelen², Aydan Mutiş³, Zeynep Erturk¹, Ruslan Asadov⁴, Tulin Ergun⁵ and Haner Direskeneli⁶, ¹Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Marmara University School of Medicine, Radiology, ISTANBUL, Turkey, ³Marmara University, School of Medicine, Rheumatology, ISTANBUL, Turkey, ⁴Marmara University School of Medicine, Radiology, Istanbul, Turkey, ⁵Marmara University, School of Medicine, Dermatology, Istanbul, Turkey, ⁶Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Vascular involvement is seen in up to 40% of the patients with Behcet's Disease (BD), especially in young males and is one of the…
Abstract Number: 1813 • 2018 ACR/ARHP Annual Meeting
Non-Aphthous Beginning As an Independent Risk Factor for the Course of Behçet’s Disease
Muhammed Aydin¹, Bahar Artim-Esen¹, Murat Inanc², Lale Ocal¹ and Ahmet Gül¹, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, İstanbul, Turkey
Background/Purpose: Behçet disease (BD) is a multisystem inflammatory disorder characterized by recurrent manifestations in mucocutaneous tissues, eyes, joints, blood vessels, intestines and brain. Since there…
Abstract Number: 2728 • 2017 ACR/ARHP Annual Meeting
Serum Levels of Interleukin-36 Receptor Antagonist in Behçet’s Patients
Pelin Ünsal¹, Pamir Cerci², Şükrü Alper Açıkgöz², Göksal Keskin² and Ümit Ölmez², ¹Ankara University School of Medicine, Ankara, Turkey, ²Immunology and Allergy, Ankara University School of Medicine, Ankara, Turkey
Background/Purpose: Behcet's disease (BD) is a systemic vasculitis disorder of unknown etiology with recurrent exacerbations and remissions. The etiopathogenesis of the disease is still unclear.…
Abstract Number: 2729 • 2017 ACR/ARHP Annual Meeting
Surgical Therapies in the Treatment of Pulmonary Artery Involvement in Behcet’s Syndrome
Hasan Tuzun¹, Gul Guzelant², Ozkan Demirhan³, Buge Oz⁴, Izzet Fresko², Vedat Hamuryudan², Hasan Yazici² and Emire Seyahi², ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Cardiovascular Surgery, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanbul Bilim University, Medical Faculty, Department of Thoracic Surgery, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical Faculty, Department of Pathology, Istanbul, Turkey
Background/Purpose: The mainstay treatment of pulmonary artery involvement (PAI) in Behcet’s syndrome (BS) is immunosuppresion and corticosteroids (1). The role of surgical intervention in the…
Abstract Number: 2732 • 2017 ACR/ARHP Annual Meeting
Recommendations for the Management of Neuro-Behcet’s Disease By the Japanese National Research Committee for Behcet’s Disease
Hirotoshi Kikuchi¹, Tetsuji Sawada², Masato Okada³, Mitsuhiro Takeno⁴, Masataka Kuwana⁴, Yoshiaki Ishigatsubo⁵, Izumi Kawachi⁶, Hideki Mochizuki⁷, Susumu Kusunoki⁸ and Shunsei Hirohata⁹, ¹Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ²Rheumatology, Tokyo Medical University, Shinjuku Tokyo, Japan, ³Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁵Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁶Department of Neurology, Niigata University Medical and Dental Hospital, Niigata, Japan, ⁷Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan, ⁸Department of Neurology, Kinki University School of Medicine, Osaka, Japan, ⁹Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan
Background/Purpose: Central nervous system involvement is one of the most serious complications in Behçet’s disease (BD). This condition is referred to as neuro-Behçet’s disease (NB)…
Abstract Number: 2744 • 2017 ACR/ARHP Annual Meeting
Long-Term Remission in Severe Behcet’s Disease Following Withdrawal of Successful Anti-TNF Treatment
Petros P Sfikakis¹, Aikaterini Arida¹, Stylianos Panopoulos², Kalliopi Fragkiadaki², George Pentazos³, Katerina Laskari³, Maria Tektonidou¹ and Nikos Markomichelakis², ¹First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, athens, Greece, ²First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece, ³Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece
Background/Purpose: Anti-TNF treatment has been shown to be effective in inducing complete remission in many Behcet’s disease (BD) patients with eye, large vessel, intestine and…
Abstract Number: 2747 • 2017 ACR/ARHP Annual Meeting
Long Term Follow-up of Behcet’s Syndrome Patients Treated with Cyclophosphamide
Mert Gurcan¹, Sinem Nihal Esatoglu¹, Vedat Hamuryudan¹, Caner Saygin², Didem Saygin³, Serdal Ugurlu⁴, Emire Seyahi¹, Melike Melikoglu¹, Izzet Fresko¹, Sebahattin Yurdakul¹, Hasan Yazici¹ and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Cleveland, OH, ³Internal Medicine, Department of Internal Medicine, Cleveland Clinic, Cleveland, Cleveland, OH, ⁴Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Cyclophosphamide (CYC) remains an important treatment option for Behçet’s syndrome (BS) pts with life threatening conditions such as arterial aneurysms. However, several adverse events…
Abstract Number: 2748 • 2017 ACR/ARHP Annual Meeting
Immunogenicity of Infliximab Among Patients with Behcet’s Syndrome: A Controlled Study
Sinem Nihal Esatoglu¹, Fatma Nihan Akkoc¹, Yesim Ozguler¹, Fatma Ozbakir², Okan Kadir Nohut², Dilsen Cevirgen³, Vedat Hamuryudan¹, Ibrahim Hatemi⁴, Aykut Ferhat Celik⁵, Hasan Yazici¹ and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Central Research Laboratory, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of and Rheumatology, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Immunogenicity of anti-TNFs has been recognized as an important problem that may cause loss of response and adverse events such as infusion reactions. We…
Abstract Number: 77 • 2017 ACR/ARHP Annual Meeting
Platelets Induce IL-1b Production in Human Monocytes through NLRP3 Inflammasome Activation
Shota Nakano¹, Hiroki Mitoma¹, Shotaro Kawano¹, Shoichiro Inokuchi², Masahiro Ayano¹, Yasutaka Kimoto³, Mitsuteru Akahoshi¹, Yojiro Arinobu¹, Koichi Akashi¹, Takahiko Horiuchi⁴ and Hiroaki Niro⁵, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ³Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, ⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁵Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: Recent studies have revealed that platelets play pivotal roles in inflammation in addition to hemostasis. The thrombus induces subsequent local inflammation and reversely the…
Abstract Number: 2775 • 2017 ACR/ARHP Annual Meeting
Critical Role of Neutrophil Extracellular Traps (NETs) in Patients with Behcet’s Disease
Alexandre LE JONCOUR^1,2, Stephane Loyau³, Nicolas Lelay⁴, Marie-Christine Bouton⁵, Antoine Dossier⁶, Anne-Claire Desbois⁷, Fanny Domont⁸, Thomas Papo⁹, Martine Jandrot-Perrus⁵, Patrice Cacoub¹⁰, Nadine Ajzenberg⁵, David saadoun⁷ and Yacine Boulaftali², ¹Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie (DHU i2B), F-75005, Paris, France., National center for Autoimmune and Systemic rare diseases and for Autoinflammatory diseases, Paris, France, ²INSERM 1148, CHU Xavier Bichat, paris, France, ³Unité INSERM 1148, CHU Xavier Bichat, Faris, France, ⁴2. Unité INSERM 1148, CHU Xavier Bichat, paris, France, ⁵Unité INSERM 1148, CHU Xavier Bichat, paris, France, ⁶3. Service de Médecine Interne, CHU Xavier Bichat, paris, France, ⁷Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie, National center for Autoimmune and Systemic rare diseases and for Autoinflammatory diseases, Paris, France, ⁸Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie, National center for Autoimmune and Systemic rare diseases and for Autoinflammatory diseases, paris, France, ⁹Service de Médecine Interne, CHU Xavier Bichat, Paris, France, ¹⁰Département de Médecine Interne et Immunologie Clinique, National center for Autoimmune and Systemic rare diseases and for Autoinflammatory diseases, Paris, France
Background/Purpose: Behçet's disease (BD) is a chronic systemic vasculitis characterised by muco-cutaneous, ocular, gastrointestinal, cerebral recurrent lesions. Venous thrombosis, is a frequent and life-threatening complication.…
Abstract Number: 1075 • 2017 ACR/ARHP Annual Meeting
Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor and Cytotoxic Potential of NK Cells in Patients with Behcet Disease
Martina Bonacini¹, Stefania Croci¹, Alessandra Soriano^2,3, Eleonora Calò¹, Alessandro Zerbini¹, Luca Cimino⁴, Francesco Muratore^2,5, Luigi Fontana⁶, Maria Parmeggiani¹ and Carlo Salvarani^2,5, ¹Unit of Clinical Immunology, Allergy and Advanced Biotechnologies, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ²Unit of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ³Campus Bio-Medico, University of Rome, Italy, Roma, Italy, ⁴Unit of Ocular Immunology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁵University of Modena and Reggio Emilia, Italy, Modena, Italy, ⁶Unit of Ophthalmology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy
Background/Purpose: Behçhet disease (BD) is a rare, systemic, inflammatory disorder with multiorgan damage and various clinical manifestations such as oral ulcers, genital ulcers and uveitis.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].